Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.15645 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Leprosy in French Guiana, 2015 to 2021: Dynamics of a Persistent Public Health Problem.
Acta Derm Venereol
May 2023
Dermatology Department, Cayenne Hospital Centre, Cayenne, French Guiana.
A resurgence of leprosy as a public health problem in French Guiana was reported over the period 2007 to 2014, particularly among Brazilians gold miners. Prolonged multidrug therapy and reversal reactions represent a therapeutic challenge. The objective of this study was to assess the evolution of leprosy in this European overseas territory.
View Article and Find Full Text PDFBiologics Beyond Boundaries: Innovative Use of Biologics in Dermatology.
Indian J Dermatol
January 2021
Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India.
Several biologic agents have been approved for use in dermatology and other disciplines of medicine. However, based on the mechanism of action and a track record of the response, these agents are being increasingly used for off-label purposes to garner control of more remote and difficult disease processes. Herein, we present three difficult to treat patients where innovative uses of biologics beyond their approved indications have yielded good responses.
View Article and Find Full Text PDFInfliximab in leprosy type 1 reaction: a case report.
Int J Dermatol
October 2021
Department of Dermatology, Andrée Rosemon Hospital, Cayenne, French Guiana.
Biologics in Leprosy: A Systematic Review and Case Report.
Am J Trop Med Hyg
May 2020
London School of Hygiene and Tropical Medicine, London, United Kingdom.
Tumor necrosis factor (TNF)-α inhibitors increase susceptibility to tuberculosis, but the effect of biologics on susceptibility to leprosy has not been described. Moreover, biologics may play a role in treating erythema nodosum leprosum (ENL). The objectives of this systematic review were to determine whether the development of clinical leprosy is increased in patients being treated with biologics and to assess the use of biologics in treating leprosy reactions.
View Article and Find Full Text PDFEtanercept in erythema nodosum leprosum.
An Bras Dermatol
October 2017
Professor Rubem David Azulay Dermatology Institute, Santa Casa de Misericórdia do Rio de Janeiro (DPRDA-SCMRJ) - Rio de Janeiro (RJ), Brazil.
One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!